Name | No. | For Patients with | Purpose |
---|---|---|---|
Beigene 311-308 / MAHOGANY | 24-30 | Relapsed/Refractory Follicular or Marginal Zone Lymphoma |
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria. |
DSSG Group: Lymphoma
firmMIND INCMOR0208-305
Name | No. | For Patients with | Purpose | |
---|---|---|---|---|
firmMIND INCMOR0208-305 | 24-05 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|